(A) Predication of interaction between miR-302a-3p and RAB22A via bioinformatics analysis. (B) Luciferase vitality in the combination within miR-302a-3p/miR-NC and RAB22A WT/MUT shown in luciferase reporter assay. ***P<0.001 vs. miR-NC. (C) Relative RAB22A expression in a normal cell line NHA and glioma cell lines. **P<0.01; ***P<0.001 vs. NHA. (D,E) Expression of predicted miR-302a-3p target genes (CROT, EDNRB, LATS2, OXR1, ZNF367, RAB22A and NR2C2) in U251 and LN229 cell lines transfected by miR-302a-3p. (F) RAB22A expressions in LN229 and U251 detected by Western blotting. (G,H) The proliferation is determined via CCK-8 assay and migration and invasion via Transwell assay in U251 transfected with control, si-RAB22A or si-RAN22A+miR-302a-3p inhibitor. Three independent experiments are conducted. Error bars represent mean ± SD of at least three experiments. **P<0.01vs. miR-NC.#P<0.05; ##P<0.01 vs. si-RAB22A.